The Failing Right Ventricle in the ICU: Silent Killer

Bedside Echo Signs, Fluid Paradoxes, Inotrope Choices, and Ventilator Impacts

Authors: Dr Neeraj Manikath ,Claude.ai

Abstract

Background: Right ventricular (RV) failure represents a critical yet often underrecognized condition in intensive care units, earning its reputation as a "silent killer." Unlike left ventricular failure, RV dysfunction presents with subtle clinical signs that can rapidly progress to cardiovascular collapse.

Objective: This review synthesizes current evidence on RV failure recognition, pathophysiology, and management in critically ill patients, with emphasis on bedside echocardiographic assessment, fluid management paradoxes, inotropic strategies, and mechanical ventilation impacts.

Methods: Comprehensive literature review of peer-reviewed articles from 2015-2024, focusing on RV failure in critical care settings.

Key Findings: Early recognition through bedside echocardiography, judicious fluid management, targeted inotropic support, and ventilator optimization can significantly improve outcomes. The traditional approach of aggressive fluid resuscitation may be counterproductive in RV failure.

Conclusions: A systematic approach to RV failure recognition and management is essential for intensivists. Understanding the unique pathophysiology and therapeutic considerations can prevent progression to refractory shock.

Keywords: Right ventricular failure, critical care, echocardiography, mechanical ventilation, inotropes

Introduction

The right ventricle has long been considered the "forgotten ventricle," yet in the intensive care unit (ICU), right ventricular (RV) failure emerges as a formidable adversary that can rapidly transform a stable patient into a hemodynamic catastrophe. Unlike its muscular counterpart, the left ventricle, the thin-walled right ventricle operates under entirely different physiological principles, making its failure a unique clinical entity with distinct management requirements.

RV failure in the ICU setting carries a mortality rate of 25-50%, with outcomes heavily dependent on early recognition and appropriate intervention.¹ The challenge lies not in the complexity of treatment, but in the subtlety of presentation and the counterintuitive nature of optimal management strategies.

Pathophysiology: The Vulnerable Right Heart

PEARL 1: The Goldilocks Principle of RV Function

The RV needs everything "just right" - not too much preload, not too much afterload, and definitely not too much positive pressure.

The right ventricle operates as a volume pump rather than a pressure pump, with several critical distinctions from left ventricular physiology:

Structural Vulnerability: The RV free wall thickness (2-5mm) is approximately one-third that of the LV (8-12mm), making it exquisitely sensitive to acute pressure increases.² This thin-walled structure, while efficient for volume handling, becomes a liability when faced with acute increases in pulmonary vascular resistance (PVR).

Pressure-Volume Relationships: The RV operates on the ascending limb of the Frank-Starling curve under normal conditions. Unlike the LV, which can tolerate significant preload increases, the RV rapidly reaches its maximum stroke volume, beyond which further volume loading becomes detrimental.³

Ventricular Interdependence: The shared interventricular septum creates a unique pathophysiological relationship. In RV failure, septal shift compromises LV filling, creating a vicious cycle of reduced cardiac output despite maintained LV contractility.⁴

HACK 1: The "D-Sign" Prediction Rule

If you see a D-shaped LV in diastole on echo, the RV systolic pressure is likely >40 mmHg. If you see it in systole too, it's probably >60 mmHg.

Clinical Presentation: The Deceptive Onset

RV failure presentation differs markedly from LV failure, often lacking the dramatic pulmonary edema and dyspnea that characterize left heart failure.

Early Signs (Often Missed):

Unexplained tachycardia disproportionate to clinical state
Subtle decrease in mixed venous saturation
Elevated lactate without obvious cause
New-onset atrial arrhythmias

Progressive Signs:

Elevated jugular venous pressure (JVP)
Hepatomegaly and right upper quadrant tenderness
Peripheral edema (late finding)
Diminished urine output despite adequate blood pressure

Late Signs (Hemodynamic Collapse):

Hypotension unresponsive to fluid resuscitation
Severe tricuspid regurgitation with systolic murmur
Hepatojugular reflux
Kussmaul's sign (JVP rise with inspiration)

PEARL 2: The Tachycardia Trap

In RV failure, the heart rate often increases before the blood pressure drops. A heart rate >100 bpm with a normal blood pressure should trigger RV assessment.

Bedside Echocardiographic Assessment

Point-of-care echocardiography has revolutionized RV failure recognition in the ICU. Unlike traditional hemodynamic monitoring, bedside echo provides real-time assessment of RV structure and function.

Essential Views and Measurements

Apical Four-Chamber View:

RV:LV ratio at the level of tricuspid annulus
Normal ratio <0.6; abnormal >1.0⁵
Qualitative assessment of RV contractility
Tricuspid annular plane systolic excursion (TAPSE)

Parasternal Long-Axis View:

Assessment of septal motion and position
D-shaped LV indicating RV pressure overload
Presence of pericardial effusion

Parasternal Short-Axis View:

Eccentricity index measurement
Regional wall motion abnormalities
RV outflow tract assessment

Subcostal View:

IVC diameter and collapsibility
Hepatic vein flow patterns
Assessment of right atrial pressure

Quantitative Parameters

TAPSE (Tricuspid Annular Plane Systolic Excursion):

Normal: >17mm
Mild dysfunction: 15-17mm
Moderate dysfunction: 10-15mm
Severe dysfunction: <10mm⁶

RV Fractional Area Change:

Normal: >35%
Mild dysfunction: 25-35%
Moderate dysfunction: 15-25%
Severe dysfunction: <15%

Tissue Doppler S' velocity:

Normal: >9.5 cm/s
Abnormal: <9.5 cm/s

HACK 2: The "60-60 Rule" for RV Pressure Estimation

If the tricuspid regurgitation velocity is >3.0 m/s AND the IVC is plethoric (>2.1cm with <50% collapse), the RV systolic pressure is likely >60 mmHg.

Advanced Echocardiographic Techniques

Strain Analysis: RV global longitudinal strain provides sensitive assessment of RV function, with normal values around -25% to -30%. Values greater than -20% suggest RV dysfunction even when conventional parameters appear normal.⁷

3D Echocardiography: When available, 3D echo provides accurate RV volume measurements and ejection fraction calculation, though technical expertise and image quality remain limiting factors.

The Fluid Paradox: When More Becomes Less

PEARL 3: The RV Fluid Paradox

The failing RV is like a water balloon - add more fluid and it doesn't get stronger, it just gets bigger and weaker.

Traditional resuscitation algorithms emphasizing aggressive fluid administration can be catastrophic in RV failure. Understanding the unique physiology is crucial for appropriate management.

Physiological Basis: The RV operates near the top of its Frank-Starling curve in healthy individuals. In RV failure, additional volume loading:

Increases RV end-diastolic pressure
Shifts the interventricular septum toward the LV
Reduces LV filling and cardiac output
Increases tricuspid regurgitation
Elevates right atrial pressure and reduces venous return

Clinical Assessment of Volume Status:

Static Indicators:

CVP >12 mmHg suggests volume overload
IVC diameter >2.1 cm with <50% inspiratory collapse
Elevated jugular venous pressure
Hepatomegaly with tenderness

Dynamic Indicators:

Passive leg raise test (PLR) with hemodynamic monitoring
Stroke volume variation in mechanically ventilated patients
Pulse pressure variation >13% suggests volume responsiveness

HACK 3: The Passive Leg Raise Test in RV Failure

If PLR increases stroke volume by >10% but the patient has signs of RV failure, they're volume responsive but volume intolerant. Give inotropes, not fluids.

Fluid Management Strategy:

Volume Assessment Protocol:

Perform bedside echocardiography
Assess RV size and function
Evaluate IVC characteristics
Consider dynamic tests if unclear

Volume Optimization:

If hypovolemic: cautious fluid challenge (250-500 mL crystalloid)
Monitor hemodynamic response and repeat echo
If no improvement or worsening RV function: stop fluids
Consider diuresis if volume overloaded

Inotropic Strategies: Tailored Pharmacotherapy

PEARL 4: The Inotrope Selection Matrix

For RV failure: Dobutamine for contractility, milrinone for afterload reduction, vasopressin for blood pressure support. Avoid norepinephrine monotherapy.

The choice of inotropic agent in RV failure requires understanding of both cardiac and pulmonary vascular effects.

First-Line Agents

Dobutamine (2.5-20 μg/kg/min):

Primary mechanism: β₁ agonist with mild β₂ effects
Increases RV contractility without significantly increasing afterload
Mild pulmonary vasodilation through β₂ receptors
Preferred agent for RV dysfunction with adequate blood pressure⁸

Advantages:

Improves RV contractility
Reduces PVR through β₂-mediated vasodilation
Maintains heart rate within reasonable range

Disadvantages:

Can cause hypotension in volume-depleted patients
May increase myocardial oxygen consumption
Potential for tachyarrhythmias

Milrinone (Loading: 50 μg/kg over 10 min; Maintenance: 0.375-0.75 μg/kg/min):

Mechanism: Phosphodiesterase-3 inhibitor
Increases cAMP, enhancing contractility and causing vasodilation
Potent pulmonary vasodilator
Longer half-life than dobutamine (2-3 hours vs 2 minutes)⁹

Advantages:

Excellent pulmonary vasodilator
Improves diastolic function
Maintains effectiveness despite β-receptor downregulation

Disadvantages:

Significant systemic hypotension
Longer duration of action complicates titration
Requires dose adjustment in renal failure

Second-Line Agents

Norepinephrine (0.1-1.0 μg/kg/min):

Use cautiously and typically in combination
Can increase PVR and worsen RV failure
Reserved for severe hypotension with adequate RV function
Consider combination with pulmonary vasodilators

Epinephrine (0.1-0.5 μg/kg/min):

High β₁ and β₂ activity at lower doses
Can improve RV contractility
Risk of tachyarrhythmias and increased myocardial oxygen demand
Reserve for severe shock states

Vasopressin (0.01-0.04 units/min):

Selective systemic vasoconstrictor
Minimal effect on pulmonary circulation
Useful for maintaining systemic blood pressure while using pulmonary vasodilators
Synergistic with other inotropes¹⁰

HACK 4: The "Milrinone Loading Trick"

When starting milrinone, give the loading dose over 30 minutes instead of 10 minutes, and start a low-dose vasopressor simultaneously. This prevents the dramatic hypotension while maintaining the benefits.

Combination Therapy

Dobutamine + Vasopressin:

Addresses both contractility and afterload mismatch
Maintains systemic pressure while supporting RV function
First-line combination for RV failure with hypotension

Milrinone + Norepinephrine:

Powerful combination for severe RV failure
Milrinone reduces PVR and improves contractility
Norepinephrine maintains systemic pressure
Requires careful balance to avoid excessive afterload

Pulmonary Vasodilator Therapy

PEARL 5: The Selective Advantage

Inhaled pulmonary vasodilators only work where there's ventilation - this creates selective pulmonary vasodilation without systemic hypotension.

Inhaled Nitric Oxide (iNO):

Gold standard for acute pulmonary hypertension
Dose: 10-40 ppm
Rapid onset and offset
No systemic hemodynamic effects
Limited by cost and availability¹¹

Inhaled Epoprostenol:

Cost-effective alternative to iNO
Dose: 30,000-50,000 ng/mL nebulized
Similar efficacy to iNO in most studies
Potential for systemic absorption and hypotension¹²

Inhaled Milrinone:

Emerging therapy with promising results
Dose: 5-10 mg nebulized every 6 hours
Combines inotropic and vasodilator effects
Limited clinical experience but theoretical advantages¹³

HACK 5: The "Poor Man's iNO"

Nebulized epoprostenol at 50,000 ng/mL gives similar pulmonary vasodilation to iNO at 1/10th the cost. Start with 30,000 ng/mL to avoid systemic effects.

Mechanical Ventilation Considerations

PEARL 6: The Ventilator-RV Interaction

Positive pressure ventilation is both friend and foe to the failing RV - it reduces preload (good) but increases afterload (bad).

Mechanical ventilation profoundly affects RV function through complex interactions with venous return, pulmonary vascular resistance, and ventricular interdependence.

Positive Effects on RV Function:

Reduced Venous Return:

Decreased preload in volume-overloaded RV
Reduced wall tension and improved coronary perfusion
Decreased tricuspid regurgitation

Reduced Work of Breathing:

Decreased oxygen consumption
Reduced sympathetic activation
Improved overall hemodynamic stability

Negative Effects on RV Function:

Increased Pulmonary Vascular Resistance:

High airway pressures compress pulmonary capillaries
Overdistension of alveoli (Zone 1 conditions)
Increased RV afterload and reduced stroke volume

Impaired Venous Return:

May reduce preload excessively in volume-depleted patients
Decreased cardiac output in preload-dependent patients

Ventilator Strategy for RV Failure:

Lung-Protective Ventilation:

Tidal volume: 6-8 mL/kg predicted body weight
Plateau pressure <30 cmH₂O (preferably <28 cmH₂O)
PEEP optimization using incremental trials
Avoid excessive PEEP that increases PVR¹⁴

PEEP Optimization:

Start with PEEP 5-8 cmH₂O
Increase incrementally while monitoring hemodynamics
Optimal PEEP: best compliance with stable hemodynamics
Consider esophageal pressure monitoring for guidance

Respiratory Rate and I:E Ratio:

Maintain pH >7.30 with permissive hypercapnia
Prolonged expiratory time (I:E ratio 1:2 or greater)
Avoid breath stacking and auto-PEEP

HACK 6: The "PEEP Sweet Spot"

In RV failure, the optimal PEEP is usually lower than you think. If cardiac output drops with PEEP increases, you've gone too far.

Prone Positioning Considerations:

Can improve oxygenation and reduce PVR
May improve RV function in ARDS patients
Requires careful hemodynamic monitoring during turns
Consider in refractory hypoxemia with RV dysfunction¹⁵

Weaning Considerations:

RV failure patients may have difficulty weaning
Spontaneous breathing increases venous return
May need extended weaning protocols
Consider non-invasive ventilation bridging

Monitoring and Assessment

Hemodynamic Monitoring

Pulmonary Artery Catheter:

Gold standard for comprehensive RV assessment
Provides direct measurement of PAP, PCWP, and cardiac output
Allows calculation of PVR and transpulmonary gradient
Risk-benefit consideration in each patient¹⁶

Key Parameters:

mPAP >25 mmHg defines pulmonary hypertension
PVR >3 Wood units indicates significant elevation
CVP >12 mmHg suggests RV dysfunction
SvO₂ <65% indicates inadequate oxygen delivery

Central Venous Pressure Monitoring:

Readily available but requires interpretation
Elevated CVP (>12 mmHg) suggests RV dysfunction
Must correlate with clinical findings and echo
Waveform analysis provides additional information

Laboratory Markers

B-Type Natriuretic Peptides:

BNP/NT-proBNP elevated in RV failure
Useful for monitoring response to therapy
Values >400 pg/mL (BNP) suggest heart failure
Higher values associated with worse prognosis¹⁷

Troponin:

Often elevated in acute RV failure
Indicates myocardial injury/strain
Higher levels correlate with worse outcomes
Serial monitoring helps assess progression

Lactate:

Elevated lactate may indicate RV failure
Reflects inadequate tissue perfusion
Goal: normalization with treatment
Persistent elevation suggests ongoing dysfunction

HACK 7: The "RV Failure Triad"

CVP >12 mmHg + BNP >400 pg/mL + lactate >2 mmol/L = significant RV dysfunction until proven otherwise.

Special Considerations

Right Ventricular Infarction

Clinical Presentation:

Inferior STEMI with hemodynamic compromise
Elevated JVP with clear lung fields
Hypotension disproportionate to LV dysfunction
Kussmaul's sign may be present

Diagnostic Approach:

12-lead ECG with right-sided leads (V3R-V6R)
ST elevation in V4R most sensitive
Echocardiography shows RV wall motion abnormalities
Cardiac catheterization for definitive diagnosis

Management Principles:

Maintain preload (avoid diuretics/nitrates)
Early reperfusion therapy
Inotropic support if hypotensive
Consider mechanical circulatory support¹⁸

Pulmonary Embolism with RV Failure

Risk Stratification:

Massive PE: systolic BP <90 mmHg
Submassive PE: RV dysfunction with normal BP
Low-risk PE: no RV dysfunction or hypotension

Management:

Anticoagulation for all patients
Thrombolysis for massive PE
Consider thrombolysis for submassive PE with high-risk features
Embolectomy for contraindications to thrombolysis¹⁹

ARDS with Cor Pulmonale

Pathophysiology:

Hypoxic pulmonary vasoconstriction
Microvascular injury and thrombosis
Mechanical compression from high airway pressures
Progressive RV dysfunction

Management:

Lung-protective ventilation strategy
Prone positioning for severe ARDS
Pulmonary vasodilator therapy
Consider ECMO for refractory cases²⁰

Therapeutic Algorithms

Acute RV Failure Management Algorithm

Step 1: Recognition and Assessment

Bedside echocardiography
Hemodynamic evaluation
Laboratory markers
Identify underlying cause

Step 2: Initial Stabilization

Optimize volume status (usually avoid aggressive fluids)
Correct hypoxemia and acidosis
Consider urgent interventions (thrombolysis, etc.)

Step 3: Hemodynamic Support

First-line: Dobutamine ± vasopressin
Second-line: Milrinone ± norepinephrine
Consider pulmonary vasodilators

Step 4: Ventilator Optimization

Lung-protective ventilation
PEEP optimization
Consider prone positioning

Step 5: Advanced Therapies

Mechanical circulatory support
Heart transplantation evaluation
Palliative care discussions

PEARL 7: The "DRIVE" Mnemonic for RV Failure**

Diagnose early with echo
Reduce afterload (pulmonary vasodilators)
Inotropic support (dobutamine/milrinone)
Ventilator optimization (low PEEP)
Evaluate for mechanical support

Mechanical Circulatory Support

Temporary Mechanical Support

Right Ventricular Assist Devices (RVAD):

Indicated for severe RV failure unresponsive to medical therapy
Can be percutaneous or surgical
Bridge to recovery, transplant, or decision
Complications include bleeding, infection, thrombosis²¹

Extracorporeal Membrane Oxygenation (ECMO):

Veno-arterial ECMO for combined cardiac and respiratory support
Veno-venous ECMO for isolated respiratory failure
Temporary support while addressing underlying cause
Consider early in appropriate candidates²²

Percutaneous Support Devices:

Impella RP: percutaneous RV support device
Limited clinical experience but promising results
Easier insertion than surgical RVAD
Bridge to recovery or definitive therapy²³

HACK 8: The "ECMO Decision Tree"

VA-ECMO if the problem is pump failure + lung failure. VV-ECMO if it's just lung failure causing RV problems. Impella RP if it's pure pump failure.

Prognosis and Outcomes

Prognostic Factors

Favorable Indicators:

Acute onset with identifiable reversible cause
Preserved LV function
Absence of severe pulmonary hypertension
Responsive to initial medical therapy

Poor Prognostic Indicators:

Chronic RV dysfunction
Severe pulmonary hypertension (mPAP >60 mmHg)
Refractory shock requiring high-dose vasopressors
Multi-organ failure
Elevated troponin and BNP levels²⁴

Mortality Predictors

CHAMPION Score Components:

Age >70 years
Chronic kidney disease
Active cancer
Chronic lung disease
Cirrhosis
Prior heart failure

Higher scores correlate with increased mortality in RV failure patients.²⁵

Future Directions and Emerging Therapies

Novel Therapeutic Approaches

Selective Pulmonary Vasodilators:

Riociguat: soluble guanylate cyclase stimulator
Selexipag: selective prostacyclin receptor agonist
Promising results in chronic pulmonary hypertension
Limited ICU experience but potential applications²⁶

Gene Therapy:

Experimental approaches targeting RV remodeling
SERCA2a gene therapy showing promise
Far from clinical application but conceptually interesting

Artificial Intelligence:

Machine learning algorithms for early RV failure detection
Predictive models using multimodal data
Potential for improved outcomes through early intervention²⁷

Biomarker Development

Emerging Markers:

ST2 (suppression of tumorigenicity 2)
Galectin-3
MicroRNAs
Metabolomic profiling

These markers may provide earlier detection and better prognostication of RV failure.

Teaching Points and Clinical Pearls Summary

OYSTER 1: The Right Heart Paradox

The sicker the RV gets, the more it looks like LV failure on physical exam (elevated JVP, edema, hepatomegaly), but treating it like LV failure (more fluids, higher PEEP) makes it worse.

OYSTER 2: The Echo Deception

A normal-looking RV on echo doesn't rule out RV failure. Look at the septum, measure TAPSE, and assess the IVC. The RV can fail without looking dilated.

OYSTER 3: The Inotrope Paradox

In RV failure, the goal isn't always to increase contractility. Sometimes reducing afterload (milrinone) works better than increasing contractility (dobutamine).

Clinical Decision-Making Framework:

High Index of Suspicion: Unexplained tachycardia, elevated lactate, or hypotension in certain clinical contexts
Rapid Assessment: Bedside echo within 30 minutes of suspicion
Avoid Harm: Stop aggressive fluid resuscitation if RV dysfunction present
Targeted Therapy: Inotropes based on hemodynamic profile
Monitor Response: Serial echo and hemodynamic assessment
Consider Advanced Therapies: Early consultation for mechanical support

Conclusion

Right ventricular failure in the ICU represents a complex clinical syndrome requiring a fundamentally different approach from left heart failure. The key to success lies in early recognition through bedside echocardiography, understanding the unique pathophysiology, and applying targeted therapeutic interventions.

The management of RV failure challenges many traditional critical care paradigms. The fluid restriction rather than resuscitation, the preference for inotropes over vasopressors, the careful balance of mechanical ventilation, and the early consideration of advanced therapies all require a nuanced understanding of right heart physiology.

As critical care medicine continues to evolve, the integration of point-of-care ultrasound, advanced hemodynamic monitoring, and emerging therapeutic options will likely improve outcomes for patients with RV failure. However, the fundamental principles outlined in this review - early recognition, physiological understanding, and targeted intervention - will remain the cornerstone of successful management.

The "silent killer" need not remain silent. With heightened awareness, systematic assessment, and evidence-based management, intensivists can unmask this condition early and intervene effectively, potentially transforming outcomes for these critically ill patients.

References

Harjola VP, Mebazaa A, Čelutkienė J, et al. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016;18(3):226-241.
Haddad F, Hunt SA, Rosenthal DN, Murphy DJ. Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation. 2008;117(11):1436-1448.
Greyson CR. Pathophysiology of right ventricular failure. Crit Care Med. 2008;36(1 Suppl):S57-65.
Belenkie I, Dani R, Smith ER, Tyberg JV. Ventricular interaction during experimental acute pulmonary embolism. Circulation. 1988;78(3):761-768.
Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography. J Am Soc Echocardiogr. 2010;23(7):685-713.
Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.
Fine NM, Chen L, Bastiansen PM, et al. Outcome prediction by quantitative right ventricular function assessment in 575 subjects evaluated for pulmonary hypertension. Circ Cardiovasc Imaging. 2013;6(5):711-721.
Kerbaul F, Rondelet B, Motte S, et al. Effects of norepinephrine and dobutamine on pressure load-induced right ventricular failure. Crit Care Med. 2004;32(4):1035-1040.
Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202.
Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation. 2003;107(18):2313-2319.
Griffiths MJ, Evans TW. Inhaled nitric oxide therapy in adults. N Engl J Med. 2005;353(25):2683-2695.
De Wet CJ, Affleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058-1067.
Haraldsson Å, Kieler-Jensen N, Ricksten SE. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: a pharmacokinetic study. J Cardiothorac Vasc Anesth. 2001;15(6):751-756.
Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.
Guérin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159-2168.
Harvey S, Harrison DA, Singer M, et al. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005;366(9484):472-477.
Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol. 2004;43(4):635-641.
O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425.
Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543

Saturday, June 21, 2025

Failing Right Ventricle in the ICU: Silent Killer